Lamin A + C Antibody Blocking Peptide

• Applications: AC
• Concentration: 1 mg/ml

Lamin A + C Antibody Blocking Peptide Summary

• Specificity: This peptide is specific for NB100-56649 only.
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: LMNA

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NB100-56649. For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -80C. Avoid freeze-thaw cycles.
• Buffer: Peptide dissolved in dH20. Contains no BSA.
• Preservative: No Preservative
• Concentration: 1 mg/ml

Alternate Names for Lamin A + C Antibody Blocking Peptide

• CDCD1
• CDDC
• CMD1A
• CMT2B1
• dilated 1A (autosomal dominant)
• EMD2
• FPLD
• HGPSFPL
• lamin A/C
• lamin A/C-like 1
• lamin-A/C
• LDP1
• LFP
• LGMD1B
• limb girdle muscular dystrophy 1B (autosomal dominant)
• LMN1IDC
• LMNC
• LMNL1
• prelamin-A/C
• PRO1,70 kDa lamin
• progeria 1 (Hutchinson-Gilford type)
• renal carcinoma antigen NY-REN-32

Background

Lamins are a class of intermediate filament proteins that form a matrix on the inner surface of the nuclear envelope. These proteins are found in many different cell types in three different forms (A, B, and C). Lamins A and C are alternatively spliced versions of the LMNA gene. The LMNA gene has been linked to many disorders of the muscular system, nervous system, and the fat distributions systems including: Emery-Dreifuss muscular dystrophy, Dunnigan-type familial partial lipodystrophy (FPLD), limb-girdle muscular dystrophy (LGMD1B), dilated cardiomyopathy (CMD1A), axonal neuropathy (Charcot-Marie-Tooth disease; CMT2B1), and mandibuloacral dysplasia (MAD).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: LMNA